JPS57156418A - Carcinostatic - Google Patents

Carcinostatic

Info

Publication number
JPS57156418A
JPS57156418A JP4110981A JP4110981A JPS57156418A JP S57156418 A JPS57156418 A JP S57156418A JP 4110981 A JP4110981 A JP 4110981A JP 4110981 A JP4110981 A JP 4110981A JP S57156418 A JPS57156418 A JP S57156418A
Authority
JP
Japan
Prior art keywords
carcinostatic
medication
bone marrow
tumor
main ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP4110981A
Other languages
Japanese (ja)
Inventor
Noboru Yoshida
Makoto Nakamura
Shigeo Ogino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Chemical Co Ltd
Original Assignee
Sumitomo Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Chemical Co Ltd filed Critical Sumitomo Chemical Co Ltd
Priority to JP4110981A priority Critical patent/JPS57156418A/en
Publication of JPS57156418A publication Critical patent/JPS57156418A/en
Pending legal-status Critical Current

Links

Landscapes

  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PURPOSE: A carcinostatic having low side effects such as bone marrow suppression, etc., exhibiting a carcinostatic action in a wide range, easily water-soluble, capable of being processed into various kinds of drug forms, having low toxicity, comprising bredinin, a nucleotide antibiotic, as a main ingredient.
CONSTITUTION: A carcinostatic comprising 4-carbamoyl-1-β-D-ribofuranosyl imidazolium-5-oleate shown by the formula or its salt as main ingredient. The compound shown by the formula exhibits a carcinostatic action not only on a heterotypic tumor such as Ehrlich carcinoma but also on a homotypic tumor such as mouse leukemia p 388, Lewis lung cancer, etc. which has been regarded as a slightly curable disease, by inventing a medication merhod such as oral medication or frequent continuous medication. High safety is observed by acute toxic test, the carcinostatic can stand a long-term use since it has very low bone marrow suppression which is found in a carcinostatic in wide use. In medication, a proper period of the stop of administration is provided, and continuous medication is carried out, to reduce the disorder degree of a host and to exhibit an extremely carcinostatic effect.
COPYRIGHT: (C)1982,JPO&Japio
JP4110981A 1981-03-19 1981-03-19 Carcinostatic Pending JPS57156418A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP4110981A JPS57156418A (en) 1981-03-19 1981-03-19 Carcinostatic

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4110981A JPS57156418A (en) 1981-03-19 1981-03-19 Carcinostatic

Publications (1)

Publication Number Publication Date
JPS57156418A true JPS57156418A (en) 1982-09-27

Family

ID=12599301

Family Applications (1)

Application Number Title Priority Date Filing Date
JP4110981A Pending JPS57156418A (en) 1981-03-19 1981-03-19 Carcinostatic

Country Status (1)

Country Link
JP (1) JPS57156418A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59227817A (en) * 1983-06-07 1984-12-21 Toyo Jozo Co Ltd Long-acting bredinin preparation for oral administration
WO1993002683A1 (en) * 1991-08-06 1993-02-18 Asahi Kasei Kogyo Kabushiki Kaisha Composition for curing proliferative skin diseases
US5472947A (en) * 1990-05-17 1995-12-05 Asahi Kasei Kogyo Kabushiki Kaisha Application of 4-carbamoyl-1-β-D-ribofuranosyl imidazolium-5-olate to the treatment of multiple sclerosis
EP0712629A1 (en) * 1987-10-28 1996-05-22 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
JP2007269814A (en) * 2000-01-26 2007-10-18 Asahi Kasei Pharma Kk Mizoribine tablet with improved color tone change
JP2011190282A (en) * 2000-01-26 2011-09-29 Asahi Kasei Pharma Kk Mizoribine tablet with improved color tone change

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF ANTIBIOTICS28 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59227817A (en) * 1983-06-07 1984-12-21 Toyo Jozo Co Ltd Long-acting bredinin preparation for oral administration
JPH0530810B2 (en) * 1983-06-07 1993-05-11 Asahi Chemical Ind
EP0712629A1 (en) * 1987-10-28 1996-05-22 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5472947A (en) * 1990-05-17 1995-12-05 Asahi Kasei Kogyo Kabushiki Kaisha Application of 4-carbamoyl-1-β-D-ribofuranosyl imidazolium-5-olate to the treatment of multiple sclerosis
WO1993002683A1 (en) * 1991-08-06 1993-02-18 Asahi Kasei Kogyo Kabushiki Kaisha Composition for curing proliferative skin diseases
US5462929A (en) * 1991-08-06 1995-10-31 Asahi Kasei Kogyo Kabushiki Kaisha Treatment of psoriasis by administration of 4-carbamoyl-1-β-D-ribofuranosylimidszolium-5-oleate
JP2007269814A (en) * 2000-01-26 2007-10-18 Asahi Kasei Pharma Kk Mizoribine tablet with improved color tone change
JP2011190282A (en) * 2000-01-26 2011-09-29 Asahi Kasei Pharma Kk Mizoribine tablet with improved color tone change

Similar Documents

Publication Publication Date Title
CA1094455A (en) Tumor antidote
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
HUS1300063I1 (en) The use of an ingenane compound for production medicament useful for treatment cancer
ES2058799T3 (en) STABILIZED COMPOSITIONS CONTAINING EPIDERMIC GROWTH FACTOR.
IL103303A (en) Pharmaceutical compositions containing ibuprofen and codeine for relief of chronic pain
HU9601846D0 (en) Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents
NO820742L (en) PROCEDURE FOR THE PREPARATION OF STABILIZED INSULIN PREPARATIONS
JPS57156418A (en) Carcinostatic
AU1206292A (en) Therapeutic agents for the treatment of multidrug resistance to cancers
EP0210753A3 (en) Anti-tumor medicament
KR900001675A (en) Compounds with bronchodilating action
ATE13488T1 (en) GALLIUM CHLORIDE, A NEW ANTI-CANCER AGENT.
KR890701526A (en) Keratosis Drug
JPS5630917A (en) Preventive and remedy for hepatitis
ES8305001A1 (en) Thiolic derivatives of erythromycin having therapeutic activity, process for their preparation and pharmaceutical compositions containing them.
CO4750645A1 (en) PREPARATION METHOD OF GRANULES INCORPORATING A MEDICINE FOR PHARMACEUTICAL USE
KR100268405B1 (en) Inhibitor for metastasis of malignant tumor
DE3163920D1 (en) Pharmaceutical preparations comprising polyprenyl compounds, especially as anti-cancer agents, and pharmaceutical compositions for the prevention and treatment of cancer and skin diseases
FI930336A (en) ANTINEOPLASTIC, CHEMOTHERAPISTIC AEMNEN, VILKA HAR ETT VEGETABILISKTURSPRUNG OCH EN I HOEG GRAD REDUCERAD TOXICITET, OCH PROCESSEN FOER ATT PREPARERA DEM
JPS5780317A (en) Preparation of pharmaceutical composition for injection
JPS5750916A (en) Carcinostatic agent
JPS5718618A (en) Antitumor agent
JPS5545659A (en) Carcinostatic agent
KR940018092A (en) Anticancer Agents of Biflavonoids from Ginkgo Leaves or Honeysuckle
FR2797446B1 (en) PHENANTHROLINE-7-ONES DERIVATIVES AND THEIR THERAPEUTIC APPLICATIONS